Atrial fibrillation, part 2

How to use antiarrhythmics and anticoagulants

J. V. Jayachanoran, J. E. Olgin, D. P. Zipes

Research output: Contribution to journalArticle

Abstract

Long-term oral antiarrhythmic therapy, attempting to maintain sinus rhythm, is warranted for some patients with atrial fibrillation (AF) and severe symptoms, even though efficacy is limited and proarrhythmia is a concern. Class IC agents, including flecainide and propafenone, are well tolerated at the usual dosages. The class III agent sotalol has β-blocking activity that may be useful in specific cases. Despite serious side effects, amiodarone can provide a reasonable balance of benefit and risk with proper patient selection, dosing, and follow-up. In the absence of specific contraindications, anticoagulant therapy to prevent thromboembolism is warranted for all patients with AF. Warfarin is recommended for high-risk patients; aspirin is appropriate for those at low risk.

Original languageEnglish
Pages (from-to)185-195
Number of pages11
JournalJournal of Critical Illness
Volume14
Issue number4
StatePublished - 1999

Fingerprint

Anticoagulants
Atrial Fibrillation
Propafenone
Flecainide
Sotalol
Amiodarone
Thromboembolism
Warfarin
Patient Selection
Aspirin
Therapeutics

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Jayachanoran, J. V., Olgin, J. E., & Zipes, D. P. (1999). Atrial fibrillation, part 2: How to use antiarrhythmics and anticoagulants. Journal of Critical Illness, 14(4), 185-195.

Atrial fibrillation, part 2 : How to use antiarrhythmics and anticoagulants. / Jayachanoran, J. V.; Olgin, J. E.; Zipes, D. P.

In: Journal of Critical Illness, Vol. 14, No. 4, 1999, p. 185-195.

Research output: Contribution to journalArticle

Jayachanoran, JV, Olgin, JE & Zipes, DP 1999, 'Atrial fibrillation, part 2: How to use antiarrhythmics and anticoagulants', Journal of Critical Illness, vol. 14, no. 4, pp. 185-195.
Jayachanoran, J. V. ; Olgin, J. E. ; Zipes, D. P. / Atrial fibrillation, part 2 : How to use antiarrhythmics and anticoagulants. In: Journal of Critical Illness. 1999 ; Vol. 14, No. 4. pp. 185-195.
@article{7cf1e8d503894d21b2dc9411acfeb367,
title = "Atrial fibrillation, part 2: How to use antiarrhythmics and anticoagulants",
abstract = "Long-term oral antiarrhythmic therapy, attempting to maintain sinus rhythm, is warranted for some patients with atrial fibrillation (AF) and severe symptoms, even though efficacy is limited and proarrhythmia is a concern. Class IC agents, including flecainide and propafenone, are well tolerated at the usual dosages. The class III agent sotalol has β-blocking activity that may be useful in specific cases. Despite serious side effects, amiodarone can provide a reasonable balance of benefit and risk with proper patient selection, dosing, and follow-up. In the absence of specific contraindications, anticoagulant therapy to prevent thromboembolism is warranted for all patients with AF. Warfarin is recommended for high-risk patients; aspirin is appropriate for those at low risk.",
author = "Jayachanoran, {J. V.} and Olgin, {J. E.} and Zipes, {D. P.}",
year = "1999",
language = "English",
volume = "14",
pages = "185--195",
journal = "Journal of Critical Illness",
issn = "1040-0257",
publisher = "Cliggott Publishing Co.",
number = "4",

}

TY - JOUR

T1 - Atrial fibrillation, part 2

T2 - How to use antiarrhythmics and anticoagulants

AU - Jayachanoran, J. V.

AU - Olgin, J. E.

AU - Zipes, D. P.

PY - 1999

Y1 - 1999

N2 - Long-term oral antiarrhythmic therapy, attempting to maintain sinus rhythm, is warranted for some patients with atrial fibrillation (AF) and severe symptoms, even though efficacy is limited and proarrhythmia is a concern. Class IC agents, including flecainide and propafenone, are well tolerated at the usual dosages. The class III agent sotalol has β-blocking activity that may be useful in specific cases. Despite serious side effects, amiodarone can provide a reasonable balance of benefit and risk with proper patient selection, dosing, and follow-up. In the absence of specific contraindications, anticoagulant therapy to prevent thromboembolism is warranted for all patients with AF. Warfarin is recommended for high-risk patients; aspirin is appropriate for those at low risk.

AB - Long-term oral antiarrhythmic therapy, attempting to maintain sinus rhythm, is warranted for some patients with atrial fibrillation (AF) and severe symptoms, even though efficacy is limited and proarrhythmia is a concern. Class IC agents, including flecainide and propafenone, are well tolerated at the usual dosages. The class III agent sotalol has β-blocking activity that may be useful in specific cases. Despite serious side effects, amiodarone can provide a reasonable balance of benefit and risk with proper patient selection, dosing, and follow-up. In the absence of specific contraindications, anticoagulant therapy to prevent thromboembolism is warranted for all patients with AF. Warfarin is recommended for high-risk patients; aspirin is appropriate for those at low risk.

UR - http://www.scopus.com/inward/record.url?scp=0033020681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033020681&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 185

EP - 195

JO - Journal of Critical Illness

JF - Journal of Critical Illness

SN - 1040-0257

IS - 4

ER -